Apple compound tested as natural muscle booster for seniors
NCT ID NCT07562698
First seen Jun 27, 2026 · Last updated Sep 03, 2026 · Updated 2 times
Summary
This study tests whether a supplement made from apple pomace (a byproduct of juicing) can improve muscle strength and physical function in older adults with mild sarcopenia—age-related muscle loss. About 105 people aged 65–80 will take either a low or high dose of the supplement or a placebo daily for 12 weeks. The main goal is to see if handgrip strength improves, along with other measures like walking speed and quality of life.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
105 people
The number who actually took part.
- Started
-
May 2026
- Finished
-
Aug 2026
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
65 to 80 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Age 65 to 80 years (inclusive) * Male or female * Community-dwelling outpatients * Able and willing to provide written informed consent * Able to comply with study procedures and attend scheduled visits * Able to walk independently (assistive devices permitted) and safely perform physical performance assessments * Stable medical condition and stable medication regimen for at least 4 weeks prior to screening * Mild sarcopenia defined as: * SARC-F score ≥4 or clinical suspicion of sarcopenia, and Low muscle strength defined as: Handgrip strength \<27 kg for men or \<16 kg for women, or Five-times chair stand test \>15 seconds or inability to complete without use of arms \- Eligible for body composition assessment using bioelectrical impedance analysis (BIA) Exclusion Criteria: * Severe sarcopenia or severe functional impairment precluding safe participation * Unstable or uncontrolled medical conditions that may interfere with participation or safety * Severe renal or hepatic disease, including: * eGFR \<30 mL/min/1.73 m² * Significant liver disease or markedly abnormal liver function tests * Uncontrolled endocrine or metabolic disorders * Active malignancy or ongoing cancer treatment * Use of medications affecting muscle mass or function, including: * Chronic systemic corticosteroids * Anabolic steroids or testosterone therapy * Other investigational muscle-modifying agents * Recent structured resistance training within the past 3 months * Use of muscle-targeted supplements (e.g., creatine, HMB) within the previous 4-8 weeks * Contraindications to BIA (e.g., pacemaker or implanted electronic device) * Acute illness within 4 weeks prior to screening * Cognitive impairment preventing informed consent or protocol compliance * Known allergy or intolerance to ursolic acid or study product components * Any condition that, in the opinion of the investigator, may compromise safety, compliance, or data integrity
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Sarcopenia are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Liaquat University Hospitals
Jāmshoro, 76090, Pakistan
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- A multi-center, randomized, double-blind, placebo-controlled, phase 1/2 clinical trial to evaluate the efficacy and safety of EN001 in patients with sarcopenia
- Skeletal muscle myosin binding protein c in fatigue and aging
- Can exercise counteract Cancer's muscle wasting?
- Hidden muscle loss in Sjögren's syndrome: a new study looks for answers
- Ancient herbal formula put to the test against Age-Related muscle loss
- Lipedema and muscle loss: is there a hidden link?